Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | HINT1 | P49773 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 4/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1299515 | 1.00 | NT5E (0.63) | NT5ETGM2HINT1ADORA3FUT5 | |
| Phosphoric Acid SCHEMBL17505120 | 0.96 | NT5E (0.61) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL4278130 | 0.96 | HINT1 (0.62) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL19938159 | 0.96 | HINT1 (0.62) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL16114092 | 0.96 | HINT1 (0.62) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL24299397 | 0.96 | HINT1 (0.62) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL13833323 | 0.96 | HINT1 (0.62) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL2510562 | 0.96 | HINT1 (0.62) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL27221934 | 0.94 | HINT1 (0.61) | NT5ETGM2HINT1ADORA3FUT5 | |
| SCHEMBL21232923 | 0.88 | HINT1 (0.56) | NT5ETGM2HINT1ADORA3STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382943-A1 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | ST PHARM CO., LTD. (KR) | 2023-11-30 | — | — | US | disclosed |
| EP-4234567-A1 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | ST Pharm Co., Ltd. (KR) | 2023-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382943-A1 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | RNGTT, RNMT, NSUN2 | NT5E 305/4885TGM2 2842/4885HINT1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.